Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine.
In Taiwan, infants need to receive 3 doses of hepatitis B virus (HBV) vaccine under the public health policy from the government. However, there are many young adults who even though received complete HBV vaccination in their childhood would lose the positive response of anti-hepatitis B surface antibody (HBs) and need the booster dose of HBV vaccine. The aim of our study is to determine the powerful predictive factor for screening the candidates who need only 1 booster dose of HB vaccine then they can regain positive postbooster anti-HBs status (≧10 mIU/mL) or protective postbooster anti-HBs status (≧100 mIU/mL).We recruited 103 university freshmen who were born after July 1986 with complete HBV vaccination in childhood, but displayed negative results for hepatitis B surface antigen and anti-HBs levels at their health examinations upon university entry. They received 1 booster dose of HB vaccine, and their anti-HBs titers were rechecked 4 weeks after the booster administration. Multivariate analysis logistic regression for positive postbooster anti-HBs status (≧10 mIU/mL, model 1) and protective postbooster anti-HBs status (≧100 mIU/mL, model 2) was done with predictive factors of prebooster anti-HBs level, body mass index, serum glutamate pyruvate transaminase level, and sex.Twenty-four students got positive postbooster anti-HBs status (10-100 mIU/mL) and 50 students got protective postbooster anti-HBs status (≧100 mIU/mL). In the model of multivariate analysis logistic regression for positive postbooster anti-HBs status (≧10 mIU/mL), prebooster anti-HBs level was the strongest predictive factor. The odds ratio was 218.645 and the P value was 0.001. Even in the model of multivariate analysis logistic regression for protective postbooster anti-HBs status (≧100 mIU/mL), prebooster anti-HBs level was still the strongest predictive factor, but the odds ratio of a protective booster effect was 2.143, with 95% confidence interval between 1.552 and 2.959, and the P value was less than 0.001.Prebooster anti-HBs level can be the powerful predictive factor for positive postbooster anti-HBs status (≧10 mIU/mL) and protective postbooster anti-HBs status (≧100 mIU/mL). According to the result of this study, if someone received complete HBV vaccination in childhood, but displayed negative results for hepatitis B surface antigen and anti-HBs levels around 2 decades later, 1 booster dose of HBV vaccine could help him or her to regain positive postbooster anti-HBs status (≧10 mIU/mL) under the strong predictive factor of prebooster anti-HBs level higher than 1 mIU/mL. The other 2 HBV vaccines could be saved and the case could also save money and time.
aDepartment of Family Medicine, E-Da Hospital bI-Shou University cDepartment of Occupational Medicine, E-Da Hospital dKaohsiung Medical University eDepartment of Anesthesia, E-Da Hospital fDepartment of Hepatology and Gastroenterology Medicine, E-Da Hospital gDepartment of Environmental and Occupational Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan ROC.
I-Cheng
IC
Lu
Mei-Chu Yen
MC
Jean
Chi-Wei
CW
Lin
Wei-Hung
WH
Chen
Daw-Shyong
DS
Perng
Chih-Wen
CW
Lin
Hung-Yi
HY
Chuang
D000293:Adolescent; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D015994:Incidence; D008297:Male; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D013624:Taiwan / Q000453:epidemiology; D014611:Vaccination / Q000379:methods*; D055815:Young Adult
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines
World J Gastroenterol. 2011 Jul 7;17(25):3054-9
21799653
Lancet. 1981 Feb 7;1(8215):289-92
6109938
Vaccine. 2007 Nov 19;25(47):8085-90
17920732
Medicine (Baltimore). 2009 Nov;88(6):349-57
19910749
Vaccine. 2013 Jan 11;31(4):584-90
23142301
Lancet Infect Dis. 2002 Jul;2(7):395-403
12127351
Science. 1993 Oct 15;262(5132):369-70
8211155
Hepatology. 1999 Mar;29(3):954-9
10051503
World J Gastroenterol. 2013 Jun 28;19(24):3861-5
23840126
World J Gastroenterol. 2011 Nov 28;17(44):4853-7
22171125
Clin Liver Dis. 2013 Aug;17 (3):375-97
23905811
Lancet. 1983 Nov 12;2(8359):1099-102
6138642
Clin Liver Dis. 2013 Aug;17(3):413-23
23905813
Vaccine. 2007 Sep 28;25(39-40):6958-64
17714836
Pediatr Infect Dis J. 2008 Oct;27(10):881-5
18756185
Hepatology. 2013 Jan;57(1):37-45
22858989
J Infect Dis. 2008 May 15;197(10):1419-26
18444799
Medicine (Baltimore). 2016 Apr;95(15):e3284
27082566
J Viral Hepat. 2012 Aug;19(8):594-600
22762144
Vaccine. 2013 Dec 17;32(1):62-8
24188755
N Engl J Med. 1980 Oct 9;303(15):833-41
6997738
Hepatology. 2004 Dec;40(6):1415-20
15565627
Soc Sci Med. 2014 Jan;101:155-65
24560236
J Viral Hepat. 2013 Nov;20(11):801-10
24168259
Vaccine. 2012 Oct 19;30(47):6623-7
22959987
Clin Liver Dis. 2013 Aug;17(3):445-50
23905815
Lancet. 2005 Oct 15-21;366(9494):1379-84
16226616
Bull World Health Organ. 1998;76 Suppl 2:152-3
10063701
Medicine (Baltimore). 2016 Feb;95(6):e2758
26871825